A Systematic Review of Genome-Wide Association Studies of Anticoagulants: A Synthesis of Methodological Quality, Ancestry Representation, and Genome-Wide Significant Genetic Variants
Summary
No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.
Summarise with VIRAT Free to try with your Science Catalogs account.Abstract
Anticoagulant medications, including vitamin K antagonists (warfarin, acenocoumarol, phenprocoumon), direct oral anticoagulants (dabigatran, rivaroxaban, apixaban, edoxaban, betrixaban), and parenteral anticoagulants (heparins, fondaparinux, direct thrombin inhibitors), exhibit substantial interindividual variability in response, with genetic factors contributing significantly to this variation. While candidate gene studies and meta-analyses have established roles for *CYP2C9/VKORC1* in warfarin response and emerging evidence implicates ABCB1, CES1, and other genes in DOAC pharmacokinetics, no systematic review has exclusively examined genome-wide association studies (GWAS) across the entire anticoagulant class. Furthermore, no review has systematically catalogued all genome-wide significant variants identified across all anticoagulants, nor evaluated how GWAS of anticoagulants are designed, conducted, and reported across diverse global populations.
Fields of Study & Subjects
Pharmacogenetics and Drug Metabolism
Genetic Associations and Epidemiology
Blood Coagulation and Thrombosis Mechanisms
Publication details
- Publication date
- 1 January 2026
- Language
- EN
- Document type
- Preprint